ES2219102T3 - Composiciones de acido fenilacetico para tratar o prevenir aterosclerosis u reestenosis. - Google Patents

Composiciones de acido fenilacetico para tratar o prevenir aterosclerosis u reestenosis.

Info

Publication number
ES2219102T3
ES2219102T3 ES99965840T ES99965840T ES2219102T3 ES 2219102 T3 ES2219102 T3 ES 2219102T3 ES 99965840 T ES99965840 T ES 99965840T ES 99965840 T ES99965840 T ES 99965840T ES 2219102 T3 ES2219102 T3 ES 2219102T3
Authority
ES
Spain
Prior art keywords
phenylacetic acid
aterosclerosis
reset
treat
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99965840T
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2219102T3 publication Critical patent/ES2219102T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de una composición farmacéutica que comprende ácido fenilacético, una de sus sales, uno de sus precursores, o uno de sus análogos, en el que dicho análogo es fenilacetilglutamina, iso-fenilacetilglutamina o la **fórmula** en la que R se selecciona del grupo formado por H y C3H7; R1 se selecciona del grupo formado por H, CH3, CH3-O-, C2H5 y C3H7; y R2 se selecciona del grupo formado por: en la que X se selecciona el grupo formado por CH3, CI, F y -OH; y n es 0, 1, 2, 3 ó 4; para la fabricación de un medicamento para el tratamiento o inhibición de reestenosis.
ES99965840T 1998-11-23 1999-11-19 Composiciones de acido fenilacetico para tratar o prevenir aterosclerosis u reestenosis. Expired - Lifetime ES2219102T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/197,903 US6127419A (en) 1998-11-23 1998-11-23 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis

Publications (1)

Publication Number Publication Date
ES2219102T3 true ES2219102T3 (es) 2004-11-16

Family

ID=22731212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99965840T Expired - Lifetime ES2219102T3 (es) 1998-11-23 1999-11-19 Composiciones de acido fenilacetico para tratar o prevenir aterosclerosis u reestenosis.

Country Status (10)

Country Link
US (1) US6127419A (es)
EP (1) EP1171110B1 (es)
JP (1) JP4536258B2 (es)
AT (1) ATE263556T1 (es)
AU (1) AU757114B2 (es)
CA (1) CA2345409C (es)
DE (1) DE69916330T2 (es)
ES (1) ES2219102T3 (es)
HK (1) HK1045253B (es)
WO (1) WO2000030627A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987131B1 (en) * 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53113032A (en) * 1977-03-09 1978-10-03 Mitsubishi Chem Ind Ltd Immune depresants
JPS54160740A (en) * 1978-06-09 1979-12-19 Takeda Chem Ind Ltd Anti-fibrotic agent
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5089508A (en) * 1990-09-04 1992-02-18 Burzynski Stanislaw R Methods for treating aids
AU655780B2 (en) * 1990-10-30 1995-01-12 Clintec Nutrition Company A method and composition for the protection of a metabolic recovery of ischemic cardiac tissue
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
US5391575A (en) * 1994-05-04 1995-02-21 Burzynski; Stanislaw R. Method for treating neurofibromatosis
US5705507A (en) * 1995-03-10 1998-01-06 Eli Lilly And Company Aplha-substituted-3-benzyl-benzofurans
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Also Published As

Publication number Publication date
JP4536258B2 (ja) 2010-09-01
WO2000030627A3 (en) 2000-11-23
WO2000030627A2 (en) 2000-06-02
DE69916330T2 (de) 2005-03-17
ATE263556T1 (de) 2004-04-15
CA2345409C (en) 2008-09-09
EP1171110A2 (en) 2002-01-16
CA2345409A1 (en) 2000-06-02
US6127419A (en) 2000-10-03
DE69916330D1 (de) 2004-05-13
EP1171110B1 (en) 2004-04-07
HK1045253B (zh) 2004-08-13
HK1045253A1 (en) 2002-11-22
AU2152800A (en) 2000-06-13
AU757114B2 (en) 2003-02-06
JP2002530328A (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BR9908275A (pt) Inibidores de enzimas fosfolipase
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
YU84400A (sh) Benzotiepini koji deluju kao inhibitori prenosa žučnih kiselina u ileumu i preuzimanja tauroholata
BR0312464A (pt) Inibidores de tirosina quinases
PT99597B (pt) Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
TR200100450T2 (tr) Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
BRPI0512951A (pt) compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
PT994884E (pt) Sais de acido difosfonico para o tratamento da osteoporose
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK1140113T3 (da) Anvendelse af bisphosphonater til profylakse og behandling af infektiøse processer
ES2219102T3 (es) Composiciones de acido fenilacetico para tratar o prevenir aterosclerosis u reestenosis.
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
NO923393L (no) Fremgangsmaate for inhibering av korrosjon i broenner som syrebehandle
DE69934113D1 (de) Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
DE60112872T2 (de) Phenylessigsäure-Zusammensetzungen zur Behandlung oder Vorbeugung von Hypercholesterolemia
BR0012502A (pt) Inibidores da expressão do gene para interleucina 5
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz